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ABSTRACT 
The genotoxicological effects of five intra-peritoneal administered oestrogens (17β-
oestradiol, daidzein, diethylstilboestrol, genistein, and equol), were examined. Male hooded-
Lister rats were used to examine to what extent DNA damage occurred. The alkaline Comet 
assay was the chosen method used to assess double-strand DNA breakage by examining the 
Olive tail moment and %age tail DNA. Tissues from the testis, bone marrow, liver and blood 
were analysed after an 8-day duration of exposure. Statistically significant increases in DNA 
damage were observed in the testis with daidzein and in the blood with diethylstilboestrol. 
In addition, a further study was carried out to examine the effects of bulk and nanotised forms 
of non-steroidal anti-inflammatory drugs (NSAIDs), aspirin and ibuprofen, in the Comet and 
micronucleus assays, on whole blood taken from prostate cancer patients or volunteers. These 
were used because it is known that the sensitivity of DNA to genotoxins can be heightened in 
patients with cancer. Patients’ and volunteers’ blood was cultured with either the bulk or 
nano-forms for 44 hours at 37°C, 5% CO2. Data were obtained for the Comet assay as above 
and the number of binucleated cells scored for the micronucelus assay. The results show the 
nanotised forms of the NSAIDs decreased the levels of strand breakage and lowered the 
numbers of micronuclei generated compared with their bulk forms. There was no clear 
difference between the sensitivity of the healthy controls and the prostate cancer patients, 
with only one individual showing evidence of heightened sensitivity. 
Keywords: hooded-Lister rats, Oestrogens, Aspirin, Ibuprofen, Nano form, Blood, 
Comet assay, Micronucleus assay, Prostate cancer. 
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GENERAL INTRODUCTION 
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1.1 Introduction 
Society demands that technologies evolve and become more efficient and financially viable. 
This has forced current manufacturing technologies, especially in cosmetics and packaging, 
to incorporate compounds with oestrogen-like properties into products as plasticisers. These 
have been implicated in increased levels of exposure and have been alleged to cause health 
associated problems (Chakraborty et al., 2012, Macon and Fenton, 2013, Molokhia and 
Perkins, 2008, Darbre, 2006, Rousseaux and Schachter, 2003). This advancement has now 
also encompassed nano-technology, which has preceded nano-toxicology, which thus lags 
behind. Therefore it is essential to examine the toxicological effects of these technologies. 
Examining engineered nano-particles using the Comet and micronucleus assays is an 
approach that should be used to assess the potential genotoxic effects of nano- forms of 
chemicals (Magdolenova et al., 2014).   
1.1.1 Oestrogenic compounds 
Oestrogenic compounds play a critical role in the pathophysiology of some diseases, 
particularly in the development of cancer. The types of oestrogen-dependent cancers vary 
depending on the tissue however breast cancers and endometrial cancers show high 
prevalence in women in the Western World. Emerging data seems to suggest a detrimental 
effect in men accounting for the oligozoospermia, which seems to be more evident in places 
such as Scandinavia (Tsourdi et al., 2009). 
Oestrogenic compounds possess the ability to cause DNA lesions via their metabolism, which 
produces reactive oxygen species (ROS). ROS compounds induce oxidative stress and 
consequently cause DNA lesions and aberrations (Anderson et al., 2003). This can lead to 
modifications both directly to the DNA (8-oxo-guanine), and as a result of enzymatic repair 
mechanisms (base excision repair, global genome nucleotide excision repair and 
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transcriptional-coupled nucleotide excision repair mechanisms). The inability for accurate 
repair and the constant onslaught of induced DNA damage causes mutations. These could 
give rise to predispositions towards some disease states and potentially lead to the 
development of cancers through the aforementioned damage (de Lemos, 2001, Kirk et al., 
2001). 
Oestrogens interact in various ways exhibiting protective effects, such as neuro-protection 
(Latourelle et al., 2010, Agius et al., 2009, DeGiorgio et al., 2002, Bonnefont et al., 1998, 
Sutcliffe et al., 2008), improved locomotor recovery from spinal cord damage (Mosquera et 
al., 2014) or protective roles in the development of atherosclerotic plaques (Newnham, 1993). 
However, oestrogens also have the capacity to generate ROS (Anderson et al., 2003, Di Santi 
et al., 2014, Yuan et al., 2014, Rettberg et al., 2014, Koong and Watson, 2014). This was 
shown in some detail involving  84 separate experiments examining sperm and lymphocytes 
in the Comet assay after treatment with the same oestrogens that were examined in the 
present study (Anderson, 2005). Catalase and superoxide dismutase were used to abolish the 
oxygen radical damaging effects showing that ROS can interact with DNA and disrupt the 
protective functions of cellular antioxidants and repair mechanisms (Anderson, 2005). 
There is a relative lack of genotoxicity data examining oestrogenic compounds in vivo. Thus 
in this study, 5 oestrogenic compounds (17β-oestradiol, daidzein, diethylstilboestrol (DES), 
genistein, and equol) were examined in thirty 12-week old sexually mature male hL rats. The 
compounds were administered via intra-peritoneal (i.p.) injection. Eight days after exposure 
(Topham, 1980), various cells were taken from the animals and analysed using the Comet 
assay.  
This paradigm is often used in risk assessment research to assess the genotoxic effects of 
potentially hazardous compounds.  Although there are some in vitro assays used for studying 
4 
 
germ cells, since there is no suitable system that adequately replicates spermatogenesis in 
vitro, reproductive research in contrast to that in somatic cells, still has a high requirement for 
in vivo assays.  
1.1.2 NSAIDs  
Nano- technology and nano-therapy have seen enormous growth in recent years. Designing 
material at this scale or by utilising properties on this scale could lead to more efficacious 
systems. This is because the altered size of the material can result in a faster mechanism of 
action as the increased surface-area: volume ratio of nano- compared with bulk-particles can 
greatly increase reaction rates. Also because of their size, cellular uptake is potentially 
enhanced, a property that is fully exploited in many cases by coating them in a lipid-soluble 
coating during their manufacture. If nanotisation of modern compounds and therapeutics has 
produced a benefit over their current usage, then many of the more long-established drugs 
(including NSAIDs such as aspirin and ibuprofen) may perhaps find new applications or be 
effective over broader dose ranges. 
The nano-forms of some agents may have a shift in their toxicity levels. For those nano-
particles with enhanced ability to cross lipid-bilayers, it is necessary now also to consider 
unintended effects on target cells (nano-toxicity). It is therefore important to be aware of 
negative aspects to the use of nano-materials. Although nano-drugs could play an important 
part in the future of medicine, appropriate nano-toxicological research to ensure safety and 
the minimisation of risks to health is necessary.   
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Figure 1.1 An illustration of the chemical structure of the oestrogenic compounds used in this study. Source: Endocr. Pract.©2008 American 
Association of Clinical Endocrinology and Human Reproduction, Oxford Journal.  
 
17-beta oestradiol Equol 
Genistein 
Daidzein 
Diethylstilboestrol (DES) 
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1.2 Oestrogenic compounds 
 It has been reported that oestrogens and their analogues have the potential to cause 
DNA lesions and show genotoxic effects upon exposure at the cellular level (Anderson et al., 
2003, Liehr, 2001, Schallreuter et al., 2006, Toyoizumi et al., 2008). These steroid hormones 
can cause the development of cancer possibly via free radical generation, an alternative 
cAMP pathway or by upregualting cellular division (Honkisz and Wojtowicz, 2014, Orostica 
et al., 2014) 
1.3 Cancer and its attributes 
Cancer is a multifactorial process, arising from dysfunction of one or more of the key 
hallmarks of normal cellular function. Diagnosis of cancer and evaluation of its prognosis is 
carried out by further investigations using scans or invasive exploration, or by measuring the 
serum levels of tumour markers present (e.g. PSA, CA12-5, CA19-9, CEA or CA15-3).  The 
presence of tumour markers in the blood has also been associated with an increased 
sensitivity of specific bloods cells to various mutagens, which is a confounding factoring in 
genotoxicity risk assessment (Malati, 2007).   
The methodology for measurement is usually a two-step process firstly using a monoclonal 
antibody specific to the marker (immunoassay), followed by a chemiluminometric analysis 
(Gardien et al., 2014). Using this approach a cohort of men with prostate cancer was 
identified and recruited to evaluate this in the course of the present studies. 
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1.4 Reactive oxygen species 
Fenton reaction: 
Fe
2+
 + H2O2 → Fe3+ + OH• + OH ‾ 
Fe
3+
 + H2O2 → Fe2+ + OOH• + H ‾ 
Harber-Weiss: 
O
•
2
‾
 + H2O2 → O2 + HO• + OH‾ 
 The above mentioned reactions describe how the generation of ROS are achieved. The 
generation of ROS through the Fenton and Harber-Weiss reactions exacerbate the insult to 
the genome from endogenously produced ROS. Thus, ROS released during mitochondrial 
respiration are widely generated during in the course of normal metabolism. In addition, 
some environmental factors, a wide range of chemicals, high oxygen use (e.g. competitive 
sports) and physiological processes involving autoimmune activation, all also increase the 
cellular burden of ROS. Such very reactive and unstable molecules may lead to genotoxicity 
by reacting with DNA, disrupting its structure and potentially its functionality 
1.5 Genetic toxicology 
Understanding what constitutes genetic toxicology and relating this research to clinical 
impact is important for preventing various disease states and possibly furthering the 
understanding of treatments and therapies. Any agent that is able to, or has the potential 
ability to, inflict genomic insult and thus cause cancerous states, is of great concern. Whether 
the genomic insult is direct or indirect the ultimate outcome remains the same. These agents 
may have a threshold, which means that they may only defer genomic insult once a certain 
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level is achieved or dosage is given. This research is vital for the pharmaceutical industry, 
government bodies, policy makers, consumers and the general public and is enshrined in law 
in most countries in the world, in a system of legally enforceable exposure limits based on the 
latest relevant genetic toxicological findings. As indicated above, the Comet and 
micronucleus assays are two such assays of importance both for regulatory and fundamental 
research. 
1.6 Comet assay 
The Comet assay under alkaline conditions allows measurement of both single-stranded and 
double-stranded breakages. This method is used through research, academic and as a tool for 
drug advisory panels on toxicity. It is a reliable, proven and reproducible method that 
incorporates a semi-automated element to decrease the time taken for analysis. The Comet 
assay also has a further advantage in that it can be used for a wide range of tissue types and 
gives information at the individual cell level. 
1.7 Micronucleus assay 
The statistical power that comes from the micronucleus assay is very considerable. Large 
numbers can be scored relatively quickly, although identification can occasionally be 
dependent on the user. The micronucelus assay is one of the methods of choice (as well as the 
Comet assay), to assess genotoxicity both for fundamental and regulatory research.  
The micronucleus assay relies on whole blood samples. If the sample is not collected 
correctly there is a risk of clots forming and making the sample unusable. 
The micronucleus assay shares many of the advantages of the Comet assay in ease of use, 
reliability and reproducibility, in providing data at the individual cell level and in its 
applicability to a range of tissues, including blood. A disadvantage of this method however, is 
9 
 
the high background frequency, which could lead to false positive results. The background 
levels of damage exaggerate genotoxicity. It is therefore important to include appropriate 
positive and negative control groups. The micronucleus assay, may fail to generate any 
results if the proper aseptic procedures are not followed. Introduction of infections in the 
early stages of analysis can occur. Although technically it is labour intensive, is it designed to 
examine cellular divisions occurring in the blood which no other method can do as 
effectively.   
1.8 Target cells 
Oestrogens are principally lipid soluble so potentially can have an effect systemically. It is 
known that the brain contains oestrogen receptors, however the incidence of brain tumours 
that could be associated with oestrogens may be low. As some of the compounds 
administered are synthetic compounds it was important to examine the liver, so see whether 
the metabolism of these compounds had an effect on the hepatic cells. 
Oestrogens are produced in the adrenal cortex, in some peripheral tissues such as adipose 
tissue and importantly in the testis. This is why the testis were examined, to determine the 
effect on the germs cells. 
In addition, the combined use of blood cells and sperm as a strategy for assessing the 
genotoxicity of compounds is well established and allows the detection of effects induced in 
any part of the body (blood cells) as well as potentially heritable effects (sperm). Therefore, it 
is suitable both for oestrogens and nano-particles. 
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1.9 Aims & Objectives 
1.9.1 Aim 
To investigate the genotoxicity of oestrogens and of nanotised or non-nanotised forms of 
NSAIDs.  
1.9.2 Objectives 
 Investigate the effects of 5 oestrogenic compounds; 17β-oestradiol and 
diethylstilboestrol, genistein, equol and daidzein in vivo and the effects these have on 
DNA migration patterns using the Comet assay on hepatic cells, bone marrow cells, 
blood and testicular cells. 
 Assess the genotoxicity of bulk and nano- forms of NSAIDs on blood taken from 
prostate cancer patients using the Comet assay. 
 Assess the toxicological potential of the nano compounds using the micronucleus 
assay. 
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
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2.1 Materials and methods 
2.1.1 In vivo study 
2.1.2 Animal procedures 
The work was carried out under the project licence from the Pharmacy Department, 
University of Bradford, and in accordance with ethical procedures and protocols, (Institute of 
Cancer Therapeutics, University of Bradford, UK).  
Experimental Design: 30 male hL rats were used to assess the genotoxic effects on various 
tissues. The controls received corn oil as the vehicle via i.p. injection and as a diluent for the 
oestrogenic compounds. The 30 rodents (5 controls and 5 treatment groups each of 5 animals) 
were killed after 8 days of exposure and cells from the testis, blood, liver and bone marrow 
were removed and the Comet assay carried out. 
2.2 Animals and Husbandry 
Sexually mature 12 week old male hooded-Lister rats, (Harlan, Bicester, UK) were chosen 
because of previous work used on this out-breed species (Sutcliffe et al., 2008, File et al., 
2003). The animals were given time to acclimatise before commencing the experiment.  Food 
and water supplies for the animals were available ad libitum. They were housed in cages with 
solid plastic sides and stainless steel grid tops and floors in a room designed for control of 
temperature (~21°C± 2°) with 45-55% humidity and light cycle (12 hours light/ 12 hours 
darkness), to mimic in situ conditions (Sutcliffe et al., 2008, Anderson et al., 1996). 
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2.3 Compound Administration  
The hL rats were weighed (from 218-244g, with an average weight of 229.12g) and these 
weights were recorded prior to administration of the oestrogenic compounds and also prior to 
sacrifice (Table 3.1). They were housed in groups of 5 and tails marked 1-4 with a blank 
indicating the control. In the Comet assay study, the compounds were administered to the rats 
with the following doses: (17β-oestradiol [50-28-2], (50 µg/kg/b.wt), daidzein [486-66-8], 
(250µg/kg/b.wt), DES [56-53-1], (100µg/kg/b.wt), genistein [446-72-0], (250µg/kg/b.wt) and 
equol [Apin Chemical-531-95-3], (250µg/kg/b.wt). All compounds except equol were 
obtained from Sigma Chemicals (Latonnelle et al., 2002, Anderson et al., 1996). The doses 
are based on previous work to establish a dose response curve (Latonnelle et al., 2002, 
Anderson et al., 1996).  
2.4 Comet assay study 
The Comet assay was conducted as described in Anderson et al., (1996), (Anderson et al., 
2003, Anderson et al., 1996, Singh et al., 1988, Tice et al., 2000). Briefly, an agarose 
‘sandwich’ is prepared on a glass slide with lysed cells between the layers and subjected to 
electrophoresis. This draws the DNA out of the nuclei forming a ‘comet tail’ when stained 
with ethidium bromide and visualised under ultraviolet light. The size and intensity of the tail 
is therefore proportional to the amount of strand breakage in the genome. 
The rats were anesthetised in a CO2 chamber according to a Schedule I killing method, 
followed by cervical dislocation. Different cell types were removed after this procedure: 
2.4.1 Bone marrow preparation 
Cells were removed from the femur after cutting the epiphyses and cells removed by 
aspiration with PBS (Anderson et al., 1996). Muscle was completely removed from the bone 
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and using 1 ml of PBS the bone marrow was flushed out. The work was not carried out under 
sterile conditions, however sterile media and aseptic technique were used to minimise the 
chances of infection occurring. The bone marrow sample was cleaned thoroughly to ensure 
no contamination with blood. 
2.4.2 Testis preparation 
The testes were carefully decapsulated with a fine forceps and tweezers and minced together 
with the epididymides. The testes were moistened in PBS buffer. A sample of 100μl was 
taken and mixed together with the second agarose layer. 70μl was added to the pre-coated 
slides, this was done in duplicate. 
2.4.3 Blood preparation 
The blood was taken from a cardiac puncture and processed immediately. 100μl of blood 
were mixed together (1:5) with RPMI- cell culture medium. This was added to 100μl of 
agarose and embedded on the slide. 
2.4.4 Liver preparation 
Once the liver had been removed it was then fragmented and cut into small pieces followed 
by homogenisation of the entire liver. This ensured the cells which were exposure to the 
oestrogenic compounds would be detected. The liver needed a further step in processing 
where trypsin was added to the cell suspension (1:5) and this was added to PBS. The trypsin 
[Gibco], digest removed the cellular matrix and individualised the cells. 100μl of the final 
cell suspension was removed and added to 100μl of 1% LMP second agarose layer and 
embedded. 
A coding system was used to for the slides and randomly scored. Each slide was given a 
random letter and slides were chosen randomly.  
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2.5 Slide staining 
60μl ethidium bromide [1239-45-8- Sigma Chemicals], (20μg/ ml) was added to each slide 
and covered with a cover slip. Care was taken not to penetrate the gel or to contaminate it by 
touching with the pipette tip. 
2.6 Slide scoring 
Slide scoring and analysis using the Comet Kinetic Imaging software
© 
4.0, Liverpool. A 
microscope linked to a florescence lens was used in conjunction with the Komet4
TM 
software 
for viewing the comet assay patterns. One hundred nuclei were scored per individual and 
mean Olive tail moment or %age tail DNA calculated per individual per group. The tail 
moment is equivalent to the integrated value of density multiplied by migration distance and 
is considered and recommended as a sensitive and reliable measurement when using various 
tissue types (Kumaravel and Jha, 2006, Hartmann et al., 2003). The reproducibility and 
number of cells which can be scored gives the Comet assay statistical power.  The parameters 
were: head threshold 2%, tail threshold 0%, smoothing value 1 (the smoothing value made 
visualisation of the real data easier by selecting the grey level and the background peak 
frequency [Anderson, et al., 1996]), background height 20; tail break length 5 (Anderson et 
al., 1996, Anderson et al., 1998), cells from each slide were analysed using the above 
software. The slides were decoded after scoring. 
 
2.7 Statistical Analysis 
In the Comet assay, the non-parametric Wilcoxon rank-sum test was performed on individual 
data.  The responses from the different cell types were compared with the negative control 
using the student t-test. Olive tail moment and % tail DNA were examined as both are 
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recommended (Jha, 2004, Stang and Witte, 2009, Tice et al., 2000). P values <0.05 were 
regarded as statistically significant. 
2.8 In vitro prostate cancer study using the micronucleus assay and Comet assay. 
2.8.1 Ethical approval 
This study was approved by Leeds (Central) Research Ethics Committee (REC reference 
number: 09/H1313/37) and the Research Support & Governance Office, Bradford Teaching 
Hospitals NHS Foundation (ReDA number: 1202).  Ethical permission was also provided by 
the University of Bradford Research Ethics Sub-Committee on Research in Human Subjects 
(reference number: 0405/8).  
2.8.2 Whole-blood sample collection: 
Blood from prostate cancer patients, suspect prostate cancer patients and healthy volunteers 
were obtained from the Ethical Tissue Bank, University of Bradford, which has approval 
from the UK Subcommittee for Research Involving Human Subjects. (Use of these samples 
was also approved as detailed above by University of Bradford ethical approval: 0405/8.) 
2.9  NSAIDs:  
Ibuprofen USP was purchased from Albermarle Europe sprl, (Belgium). Pharmcoat 606 
(HPMC) was kindly donated by Shinetsu (Japan). Bulk and nano-suspensions of ibuprofen 
were prepared by Lena Nanoceutics (University of Bradford, UK), (Najafzadeh et al., 2012). 
2.9.1 Nano-material methodology  
Suspensions of ibuprofen with solid loads of 3% and 4% (w/w) respectively were prepared. 
The suspending medium consisted of: HPMC (0.5%, w/w), polyvinylpyrrolidone K-30 
(0.5%, w/w) and sodium lauryl sulphate (0.1%, w/w) in deionised water (Plakkot et al., 
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2011). The milling was carried out using Lena nanoceutics technology DM-100 machine 
(Sulaiman, 2007).  
250 ml of each suspension were milled using 150 ml of 0.2 mm yttrium stabilised zirconium 
beads (Glen mills, USA). The materials were recycled for 60 min in the milling machine 
before being discharged in an opaque glass bottle and stored in the refrigerator at (4°) for the 
duration of the experiments, (Najafzadeh et al., 2012).   
2.9.2 Particle size and analysis 
The particle size distribution of aspirin and ibuprofen nano-suspensions were determined 
using the dynamic light scattering technique of the Zetasizer Nano ZS (Malvern instruments, 
UK). Samples were measured at room temperature using disposable sizing cuvettes. All 
measurements were carried out in triplicate. The particle size of the stock suspensions were 
measured in triplicate immediately after milling and then rechecked at the end of the 
experiments to ensure no significant change in particle size occurred during the various 
phases of the experiments. The particle size of the bulk powder was measured using the laser 
diffraction technique (Sympatec Helos, UK). Approximately 20 mg of each drug were 
transferred into the sample vial and the primary pressure was adjusted to 4 bars while the 
feeder speed was 40mm/s. Three samples of each drug were measured using R2 lens 
(0.25/0.45, 87.5µm). 
2.9.3 Zeta potential 
The zeta potential for suspensions is the frequency shift depending on the magnitude of the 
nano-particle size (mV). This was determined using Zetasizer Nano ZS (Malvern 
instruments, UK). The suspensions were diluted 1:100 using deionised water and measured at 
25°C. Clear disposable zeta cells were used. Measurement duration was set as automatic with 
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a minimum of 10 runs and a maximum of 100 runs. All measurements were made in 
triplicate, (Najafzadeh et al., 2012). The definition for size of any given nano-medicines set 
by The National Cancer Institute (NCI), which is: nano-particles are particles with sizes 
between 1 and 100nm. Nano-particles are composites of therapeutic agents and synthetic 
carriers of materials, (Najafzadeh et al., 2012). 
2.10 The Cytokinesis blocking micronucleus (CBMN) Assay  
Micronucleus assay reagents General Laboratory reagents were purchased from Fisher 
Scientific Co. (Itasca, IL). RPMI 1640 medium (with L-glutamine and 25 mM Hepes), 
Cytochalasin B (Cat No. C6762) and mitomycin C (Cat No. M0503) were purchased from 
Sigma-Aldrich (Poole, UK), penicillin-streptomycin solution (Cat No.15140-122) were 
purchased from Invitrogen Ltd, UK. Slides and cover slips were obtained from VWR 
international. The Fixogum rubber cement was purchased from (Marabu, Germany). Patient 
blood was collected into lithium-heparin tubes (vaccuette containers). 
2.11 Micronucleus assay protocol: 
The samples were cultured and handled within sterile conditions. Patient blood was added to 
culture flask. One hundred µl of PHA was added to each of the culture flasks containing the 
400µl of whole blood and incubated at 37°C in conditions of 5% CO2. At the 44-hour 
interval, 30µl 1mg/ml Cytochalasin B was added for a final concentration of 6µg/ml. 
Micronuclei are found in the precursors of erythrocytes in whole blood. 
2.11.1 Cell preparation 
At the 72 hour time point, the cultures were transferred and centrifuged for 8mins, 800RPM 
(110xg). The supernatant was removed and cells resuspended. Hypotonic shock was carried 
out by exposing the cultured cells to 90mM KCl for 15mins at 4°C. 
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 Cultures were then centrifuged and the supernatant removed and cells resuspended. 5ml of 
Carnoy’s solution was added followed by 3 drops of formaldehyde to each culture. A further 
centrifugation step was followed and, again, the supernatant was removed and the cells were 
resuspended. This fixation step was repeated twice further. 10µl of cell suspension was 
applied to microscope slides and then stained using freshly prepared 5% Giemsa in Sorensen 
buffer, pH 6.8- filtered twice using Whatman 41 filter paper. Once the slides had been rinsed 
thoroughly, and left to dry (preferably over night), cover slides were mounted onto the slides 
using Fixogum rubber cement. 
2.12 Cell scoring  
Using bright-field light microscopy at 1000 x magnification, slides were scored using criteria, 
as recommended by Fenech et al., (2003; 2007).  MNi were scored each from binucleated 
(BiNC) and mononucleated (MonoNC) cells. The nuclear division index (NDI) was used as 
an indicator of the cytotoxicity and the following calculation was used to find the NDI: NDI 
= (M1 + 2(M2) + 3 (M3) /N  
Where: M1 = mononucleated cells, M2 = binucleated cells, M3 = multinucleated cells, N = 
the total number of viable cells scored. The number of cells scored for the investigation was 
1000 cells /person/ treatment group.  
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CHAPTER 3 
 
 
IN VIVO STUDY USING THE COMET ASSAY 
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3.1 Introduction  
There is a lack of genotoxicity data examining oestrogenic compounds in vivo. Thus 
in this study, 5 oestrogenic compounds (17β-oestradiol, daidzein, diethylstilboestrol (DES), 
genistein, and equol) were examined in thirty 12-week old sexually mature male hL rats. The 
compounds were administered via i.p. injection, as this method of administration has been 
used before (Rakhila et al., 2014, Pinto et al., 2006). Eight days after exposure, various cells 
were taken from the animals and analysed using the Comet assay. Cells were examined at this 
time point because previous studies have shown genetic effects on both sperm and somatic 
cells eight days after exposure, (Anderson et al., 1996, Topham, 1980b).  
3.1.1 Materials and methods.  
 
The methods used in this chapter have been described in chapter 2. 
 
3.2 Results 
Table 1 shows the weights of the rats prior to administration of the compounds and before 
sacrifice. There were no differences in the weights of the animals after dosing and before 
sacrifice, except in the group dosed with genistein, showing that compounds have no adverse 
effects. 
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Corn oil  Rat weight at dose (gms) weight prior to killing (gms) 
Vehicle Control 218 284 
Vehicle Control 230 297 
Vehicle Control 232 296 
Vehicle Control 229 288 
Vehicle Control 244 312 
Mean wt. (gms) 230.6 295.4 
Dose 50mg/kg/b.wt.   
17β-oestradiol 219 285 
17β-oestradiol 231 290 
17β-oestradiol 230 290 
17β-oestradiol 215 288 
17β-oestradiol 231 266 
Mean wt. (gms) 225.2 283.8 
p=values p=0.34 p=0.12 
Dose 100mg/kg/b.wt.   
DES 228 298 
DES 221 270 
DES 239 302 
DES 232 300 
DES 228 269 
Mean wt. (gms) 229.6 287.8 
p=values p=0.85 p=0.42 
Dose 250mg//kg/b.wt.   
Genistein 232 307 
Genistein 226 390 
Genistein 244 314 
Genistein 233 285 
Genistein 239 281 
Mean wt. (gms) 234.8 315.4 
p=values p=0.44 p=0.35 
Dose 250mg//kg/b.wt.   
Daidzein 219 298 
Daidzein 223 284 
Daidzein 225 287 
Daidzein 224 303 
Daidzein 230 300 
Mean wt. (gms) 224.2 294.4 
p=values p=0.19 p=0.87 
Dose 250mg//kg/b.wt.   
Equol 227 290 
Equol 228 294 
Equol 231 291 
Equol 235 312 
Equol 230 274 
Mean wt. (gms) 230.2 292.2 
p=values p=0.93 p=0.69 
Table 3.1 Rat weights (gms) at dosing and prior to killing on day 8.  P values compared to the vehicle control 
group (student’s t-test). 
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3.3 The Comet assay 
Figures 3.1 and 3.2 show images of comets in lymphocytes and sperm. Viewing 
magnifications are given for all figures. 
  Figure 3.1 Comet images of lymphocytes 
Figure 3.2 Comet images of sperm. 
x400 
X200 
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Figures 3.3-3.6 show the Olive tail moment and % tail DNA for cells from the liver, testis, 
blood and bone marrow respectively. Whilst there were some variations in the values with the 
different oestrogens, the only two values that have statistical significance by comparison with 
the negative control were testicular cells treated with daidzein for % tail DNA (p= 0.043) 
[Figure 3.4] and similarly blood cells treated with DES (p= 0.034) [Figure 3.5]. 
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Figure 3.3. The Olive tail moment and % tail DNA for cells from the liver. Data are expressed as mean ±SEM 
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Figure 3.4. The Olive tail moment and % tail DNA for cells from the testes *significance by comparison with the negative control (p=0.043). Data are 
expressed as mean ±SEM 
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Figure 3.5. The Olive tail moment and % tail DNA for cells from the blood. *significance by comparison with the negative control (p=0.034). Data 
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Figure 3.6. The Olive tail moment and % tail DNA for cells from the bone marrow. Data are expressed as mean ±SEM 
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3.4 Discussion 
This study was designed to investigate the effects of 5 oestrogenic compounds in vivo to 
determine whether DNA damage occurred and if so to what extent. The five oestrogens were 
chosen because all have been shown to produce oxidative stress in a total of 84 experiments 
in vitro in the Comet assay both in lymphocytes and sperm. This stress can be abolished in 
the presence of catalase and to a lesser extent with superoxide dismutase, as discussed earlier 
(Anderson et al., 2003), which indicated that DNA damage could possibly occur in vivo.  
The study did not use a positive control group that could lead to DNA effects in the tissues of 
interest because there is not one available for the four tissues investigated. However, the 5 
oestrogenic compounds have previously all shown to be positive in sperm and lymphocytes, 
so the timing of the response determination was based on that for bleomycin operating 
through an oxidative stress mechanism previously detected in vivo (Anderson et al., 1996). It 
is suggested that bleomycin works by chelating metal ions, producing a component which 
reacts with oxygen and this produces free radicals. Also DES produced a response in post 
meiotic germ cells (sperm head abnormalities), after a single i.p. dose (Topham, 1980a). It is 
known that alkylating agents like ethyl and methyl methane sulfonate are positive in post-
meiotic germ cells after a single dose and chemicals like the antimetabolites methotrexate and 
mercaptopurine are positive in meiotic germ cells and ethyl and methyl nitosourea are 
positive in pre-meiotic germ cells. DES falls into the first category. 
It is recognised that there are statistically significant effects for one Comet parameter; % tail 
DNA but not for Olive tail moment. These results are relatively minor and therefore require 
confirmation by further investigation. The Olive tail moment is suggested to be an 
appropriate index of induced DNA damage in considering both the migrations of the genetic 
material as well as the relative amount of DNA in the tail. Another dose to show toxicity to 
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the target tissue has to be investigated to confirm negative results. Further work could 
investigate this. 
It is well known that oestrogens can produce hazardous effects in humans by disrupting the 
spermatogenic cycle by impairing spermatogenesis (Nakazumi et al., 1996).  
The criteria used to choose the tissues used in this study were to include testicular cells 
corresponding to sperm, and blood, corresponding to lymphocytes, of an earlier in vitro study 
(Anderson et al., 2003). The reasoning behind the choice of dose was based on a conversion 
of the concentrations /doses of our in vitro study from µg/ml to mg /kg body weight (equating 
1ml of medium in vitro to 1g body weight in vivo) and intra-peritoneal injection. This was the 
most common route of exposure for the single dose dominant lethal studies (Anderson et al., 
1996) in male rodents and other effects on sperm (Topham, 1980a), on which this study was 
based.  
There are 2 ways to carry out a dominant lethal assay in males treated once i.p. The original 
method in which male animals are mated for eight weeks (mice) or ten weeks (rats) to virgin 
female mice over the spermatogenic cycle and mated once a week or every few days to 
determine at which stage of the spermatogenic cycle the chemical is at its most active. There 
is a second method where animals are mated after 2 doses, one non-toxic and one toxic. The 
animals are mated for 8-10 weeks and sampled twice. The toxic dose will ensure that the 
animal received the compound when a negative response is seen.  
Oestrogenic compounds play an antioxidant and pro-oxidant role in normal cellular 
homeostasis. e.g. it is known that oestrogens have a neuro-protective role in the brain, but  
can also be involved in the development of atherosclerosis, which involves oxygen radical 
damage (Newnham, 1993). 
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The generation of ROS occurs through every day normal metabolism and metabolic events. 
Reactive oxygen species exist due to a loss or gain of an electron from a non-radical species. 
During the de novo synthesis of ROS, mechanisms exist in vivo to limit the amount of 
damage. The GG-NER and BER mechanisms repair DNA lesions while actions of 
antioxidants such as catalase, superoxide dismutase and glutathione peroxidase, convert the 
radicals into non reactive species (Anderson et al., 1996, Schallreuter et al., 2006). It is 
understood that the generation of ROS through the Fenton and Harber-Weiss (Schallreuter et 
al., 2006) reactions help perpetuate the assault on the genome. Crucial to these reactions are 
the unstable species that remove electrons from other substrates to help stabilise the structure 
of the oxygen molecules 
Ultimately, alterations produced this way will cause cellular dysfunction and promote tumour 
development mediated through the generation of ROS damaging the DNA (Anderson et al., 
2003). 
In this study weights did not differ significantly from the vehicle control, suggesting there 
were unlikely to be adverse effects due to weight changes. Imply by recording the weights of 
the rats can give you an indication to onset of pathogenesis. Genistein showed a slight 
increase in weight. This may have been due to the fact that is it a phytoestrogen, but daidzein 
which is also a phytoestrogen showed no weight gain.  Daidzein and DES produced 
responses of borderline statistical significance in % tail DNA in the testis and blood. A longer 
duration after exposure to the oestrogenic compounds may cause further or less DNA damage 
to occur, depending on normal cellular repair mechanisms. This was not the case for the 
testis, where the damage was measured in the late spermatid stage of the spermatogenic 
cycle, where it was most likely to occur. For another agent, bleomycin, which involves an 
oxygen radical mechanism, the effect was examined at a similar stage after treatment, as 
discussed earlier (Anderson et al., 1996). The oestrogens were also given as a single acute 
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dose in this study. This may have affected the bioavailability of the oestrogens, but to what 
extent is unknown.  
Oestrogens can be converted to catechol oestrogen-3,4-quinones and oestradiol-3,4-
quinone becoming electrophilic metabolites, which react with DNA forming depurinating 
adducts (Cavalieri and Rogan, 2006). Oxidation of catechols to semiquinones and quinones is 
a mechanism of tumour initiation. The same can be said for synthetic oestrogens such as 
DES. It is known that some oestrogens e.g. genistein is an isoflavone found in many different 
types of soy beans and meats and has the ability to act as an antagonist to oestradiol without 
creating the genomic effects because it is unable to recruit necessary co-transcriptional 
factors due to its conformation (de Lemos, 2001, Merritt and Jenks, 2004). 
In conclusion, in male hL rats, i.p. administration of the oestrogenic compounds 
produced borderline statistically significant increases in DNA damage seen in vivo in the 
testis with daidzein and blood with DES.  
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CHAPTER 4 
 
 
THE GENOTOXIC EFFECTS OF NANO- AND BULK FORMS OF NSAIDS ON BLOOD 
 
 SAMPLES FROM PROSTATE CANCER PATIENTS 
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4.1 Introduction 
Biomedical sciences research endeavour to determine new and innovative approaches to treat 
patients. The development of nano-materials and particles bring the possibility of a more 
direct approach to treatment limiting unwanted side effects. Developments of nanotised 
therapeutic drugs are fast approaching the clinical trial phases. These new forms of 
therapeutic drugs and materials need to stand up to the rigours and scrutiny of patient safety, 
risk assessments and toxicological screens. Therefore we must further our understanding of 
the safety of these materials as well as the mechanisms of action. 
Data from epidemiological studies carried out in 2012, indicate that over 25% of all cancers 
are related to chronic or unresolved inflammation (Vendramini-Costa and Carvalho, 2012). A 
prime example of this is seen in patients who are diagnosed with mesothelioma. The chronic 
inflammatory response is initiated by the presence of asbestos fibres that the immune system 
is incapable of removing.  The accumulation of macrophages release tumour necrosis factor- 
α (TNF-α) and NF-kB. These pro-inflammatory proteins promote the use and exposure of 
ROS and other potential mutagens to the mesothelial cells.   
4.2 Prostate cancer 
This part of the study investigated the effects of nanotised forms of NSAIDs. The study used 
blood taken from patients with known or suspected prostate cancer and looked at the effects, 
comparatively, against the nano and bulk forms of the NSAIDs. 
 Prostate cancer is thought to be the second highest cause of cancer deaths in men. Androgens 
potentiate and sustain abnormal cellular growth of the prostate gland. Anti-androgen 
treatment is effective and is the recommended treatment administered. Epithelial cells of the 
prostate gland produce a tumour marker which is used to assess both the prognosis and 
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diagnosis of prostate cancer. An increase in prostate specific-antigen (PSA) are associated 
with benign prostatic hyperplasia, enlargement of prostate gland, and changes in the 
transitional zone in the urethra are seen.   
In Europe, it was estimated that 417,000 new cases of prostate cancers were diagnosed of 
which 92,300 would have died. Worldwide more than 1.11million men were estimated to 
have been diagnosed in 2012, of which 307,000 fatalities were estimated (Cancer Research 
UK 2012). 
4.3 Detection and measurement of PSA 
The PSA method is used in conjunction with digital rectal examination to aid the detection of 
prostate cancer. PSA is detected in males with normal, benign hypertrophic and malignant 
prostate tissue. One commonly used method for measurement by many NHS trusts in the UK 
uses a Siemens Advia Centaur. The PSA assay is a two-site sandwich immunoassay with 
direct chemiluminescence technology, which uses constant amounts of two antibodies. The 
first antibody, in the ‘lite-reagent’ phase, is a polyclonal goat anti-PSA antibody labelled with 
acridinium ester. The second antibody, in the solid phase, is a monoclonal mouse anti-PSA 
antibody, which is covalently coupled to paramagnetic particles. 
Solid phase and lite reagent are added to the sample; separation, aspiration and washing take 
place, then acid and base reagent are added to initiate the chemiluminescent reaction. A direct 
relationship exists between the amount of PSA present in the patient sample and the amount 
of relative light units detected by the analyser 
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Table 4.1.Guidelines from the Royal College of Pathology- PSA levels. 
4.4 Material and methods 
These are detailed in Chapter 2.  
4.5 Experimental Aim 
Our experimental aim is to see whether the effects of nanotised NSAIDs compared to their 
bulk forms show an increase or decrease in micronuclei. We know from previous work 
carried out from our lab (Anderson et al., 2014), that patients with diagnosed cancer, have 
sensitised lymphocytes and are more prone to genomic insult. Thus we wish to determine 
whether sensitised lymphocytes will exhibit a higher or lower numbers of micronuclei, 
indicating the toxicity of the nanotised drugs, and whether this be can assist in assessing the 
clinical use for nanotised NSAIDs. 
The drugs to be investigated are aspirin and ibuprofen as show in figure 4.1-4.2 
 
 
 
 
   
  
Reference Interval Male: 
Up to 49 years old: <2 ug/L. 
50 – 59 years old: <3 ug/L. 
60 – 69 years old: <4 ug/L. 
Greater than 69 years old<5 ug/L. 
 
The chemical structure of ibuprofen The chemical structure of aspirin 
(acetylsalicylic acid) 
Figure 4.1 Showing the structural formulae of ibuprofen and aspirin 
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4.6 Results 
The size for the nano particles used in the present study are shown below. (These data have 
been generated by Dr M. Isreb, School of Pharmacy, University of Bradford). They are in the 
desired range. 
Suspension name  Time of 
measurement  
Average particle 
size (nm)  
Polydispersity 
index (arbitrary 
units)  
Zeta potential 
value (mV)  
Ibuprofen nano-
suspension 3% 
Before cells 
treatment  
323±6.4  0.2± 0.01  -2.1 
After cells 
treatment 
340±1.2  0.3±0.001   
Aspirin nano-
suspension 4% 
Before cells 
treatment 
289±3 0.3±0.03 -6.1 
After cells 
treatment 
299±6.3 0.3 ± 0.05  
 
Table 4.2 Average particle size, polydisersity index and zeta potential values of the nano-
suspensions. (n=3). 
Suspension name  
 
Average particle size (μm)  
 
Volume Mean Diameter(μm)  
 
Ibuprofen  
 
52.80 ± 4.37  
 
20.50  
 
Aspirin  
 
78.30 ± 0.23  
 
44.57  
 
 
Table 4.3: Average particle size (x90) and the volume mean diameter of the bulk powder (as 
received) of aspirin and ibuprofen (n=3). 
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The micronucleus assay data is shown in table 4.4. Blood taken from two prostate cancer 
patients were investigated at 3 doses. The highest dose was toxic to the cells. Only ibuprofen 
data are shown, as the nano particles of aspirin conglomerated. For ibuprofen the bulk version 
produced more micronuclei than nanotised form. In both patients showed similar results for 
binucleated and mononucleated cells. Table 4.5 shows the NDI and values are within the 
acceptable range 
In figure 4.2, Olive tail moments were compared in the nano and bulk versions of aspirin and 
ibuprofen in controls, and in suspected and diagnosed prostate cancer patients. In general, the 
nano version produced lower responses than the bulk versions but statistical significance was 
not achieved. 
The data contributing to figure 4.2 are presented in Table 4.6, confirming that in general, the 
nanotised forms of the drugs showed lower levels of damage than the bulk forms or the 
controls. Furthermore, in the prostate cancer patients and controls, levels of damage were 
highest with the bulk forms. However, statistical significance was not achieved. 
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Drug Dose Form Group NDI Drug Dose Form Group NDI 
     
     
IBU 250 Bulk 1 1.84 IBU 250 Bulk 2 1.83 
IBU 250 Nano 1 1.87 IBU 250 Nano 2 1.90 
IBU 500 Bulk 1 1.72 IBU 500 Bulk 2 1.89 
IBU 500 Nano 1 1.87 IBU 500 Nano 2 1.92 
 
 
 
  
Table 4.5. The scored micronuclei comparing the bulk and nanotised versions. Due to conglomeration of nano-particles used, results from aspirin 
analysis are not shown. 
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Figure 4.2. After a dose response was established, the nano NSAIDs were compared to their bulk versions using the OTM. Clastogenicity of the bulk 
and nano forms of the compounds are compared.  
Analysis of NSAIDs using the Comet assay 
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  Control ASP Bulk 
ASP 
Nano 
IBU 
Bulk 
IBU 
Nano 
 Healthy controls (n=3) 1.85 3.95 1.74 3.24 1.21 
 Suspect prostate cancer patients (n=2) 2.01 1.85 1.68 2.16 1.77 
 *Prostate cancer (n=3) excluding outlier 2.32 3.6 2.64 3.14 2.66 
 **Prostate cancer (n=3) including outlier       3.14 3.71 
 
       Test group Code 
     Prostate Cancer 5072PC 2.89 4.51 2.67 4.30 5.78 
  5169PC 1.80 2.73 2.11 2.08 2.64 
  5329PC 2.28 3.57 3.14 3.04 2.70 
  Mean 2.32 3.60 2.64 3.14 3.71 
Suspect Prostate Cancer 5081SPC 2.12 1.98 1.97 2.07 1.99 
  5082SPC 1.91 1.71 1.39 2.25 1.54 
  Mean 2.01 1.85 1.68 2.16 1.77 
Controls 37cont 1.77 7.77 2.39 6.90 1.37 
  
J12-6-13 
cont 
2.00 2.55 1.72 1.19 1.11 
  
O12-6-13 
cont 
1.79 1.54 1.10 1.65 1.14 
  Mean 1.85 3.95 1.74 3.24 1.21 
Table 4.6. Raw data generated from the Comet assay.   
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4.7 Discussion 
In this study, DNA damage in peripheral lymphocytes blood samples of individuals with 
suspected and diagnosed prostate cancer have been compared to healthy controls. Treatments 
with either the bulk (suspension was prepared from the powders as received) and nano-drug 
versions of aspirin and ibuprofen in the micronucleus assay using the method of Fenech 
(2007). 
Chronic inflammation is now known to contribute to several forms of human cancer, with an 
estimated 20% of adult cancers attributable to chronic inflammatory conditions caused by 
infectious agents, chronic non-infectious inflammatory diseases and/or other environmental 
factors. There is evidence for a role for chronic inflammation in prostate cancer aetiology, 
with a specific focus on recent advances regarding the following: (i) potential stimuli for 
prostatic inflammation; (ii) prostate cancer immunobiology; (iii) inflammatory pathways and 
cytokines in prostate cancer risk and development; (iv) proliferative inflammatory atrophy 
(PIA) as a risk factor lesion to prostate cancer development; and (v) the role of nutritional or 
other anti-inflammatory compounds in reducing prostate cancer risk (Sfanos and De Marzo, 
2012). 
There is some speculation that infection in the prostate gland may be responsible for the 
chronic immune response. This chronic inflammation could be the main factor initiated in the 
release of ROS in the microenvironment, thus giving the rise to cancer. In 2009 a study at 
Queen’s University, Belfast, investigated whether Propionibacterium acne may be a cause 
for prostate cancer by causing a chronic inflammatory response.  
The evidence from our work suggests that there is a reduction in the number of micronuclei 
formed when exposed to the nanotised version and compared with their bulk counterparts. As 
the nano-particles could enter the cells more readily, they could possibly forego some of the 
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interactions that usually occur when administering drugs. Our studies seems to validate other 
studies we have carried out in our laboratory on nano-toxicology; however the link between 
prostate cancer, ROS, nanotised NSAIDs and toxicology is relatively undiscovered. We have 
found that there is a decrease in MN formation. Similar effects of NSAIDs on cancer have 
been described by Park, et al (2014). This could be explained by possible direct beneficial 
effect on cancers and tumour biology (Park et al., 2014). This can been further seen from the 
down-regulation of the inflammatory response from within the tumour microenvironment 
(Hussain et al., 2012). 
The methods used in these investigations were chosen because these methods are described in 
the OCED guidelines on carrying out toxicological studies. The reproducibility, effectiveness 
and statistical power means that these methods can incorporate a wide range of different sized 
studies whilst be reliable in its accuracy and precision. Although the Comet assay is semi-
automated, there is still the element of background inferences which can cause bias. 
Likewise, with manual scoring of the micronuclei. The clear definition of a micronuclei can 
be different from one researcher to another. Although the Comet assay is more susceptible to 
background noise, current methods in combination with software improvements mean that 
interferences are reduced.  
The data generated from the Comet assay, although the n numbers in each group were small 
and statistical significance was perhaps therefore not achieved, demonstrate a clear reduction 
in the levels of genotoxicity of the nano-forms, although the suspected prostate cancer patient 
did not follow this trend. This may have been because these patients do not necessarily have 
prostate cancer and maybe suffering from other pathologies and have other, unknown, 
treatments. This reduction in toxicity is interesting and potentially important as it suggests 
that possibly increasing the reactivity of these drugs by nanotising the particles might not 
increase toxic interactions. Nano-NSAIDs may thus be not only more effective but also safer. 
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DISCUSSION  
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5.1 General discussion 
The extent of genotoxicity of 5 oestrogens in vivo in male hL rats, as well as the effects of 
nanotised non-steroidal anti-inflammatory drugs on prostate cancer patients have been 
examined. Potentially, both may involve reactive oxygen species at the centre of their 
mutagenicity. Technologies evolve to become more efficient and financially viable, as in the 
case of nano-technology, but toxicology must keep pace with this evolution. As with many de 
novo pathways and mechanisms within the body, defects and disruptions and can lead to an 
unregulated and uncontrolled response as seen in cancer. The effects of ROS and their 
unwanted responses have had much scientific scrutiny and investigations because of their 
association with cancer development. It is believed that ROS play a crucial role in the 
generation of cancer. 
In this in vivo study, responses were seen with daidzein in testis and DES in blood. 
Oestrogens can be converted to catechol oestrogen-3,4-quinones and oestradiol-3,4-quinone 
becoming electrophilic metabolites, which react with DNA forming depurinating adducts 
(Cavalieri and Rogan, 2006). Oxidation of catechols to semiquinones and quinones is a 
mechanism of tumour initiation. The same can be said for synthetic oestrogens such as DES.  
NSAIDs represent a critically important class of medications useful in numerous 
musculoskeletal and inflammatory diseases which also involve oxygen radical damage. As 
NSAIDs may regulate NAG-1 protein expression, this may mediate induction of ROS by 
initiating the associated intrinsic pathways (Vaish et al., 2013). This significant enhancement 
of intracellular ROS in turn increases apoptosis.  
There is increasing evidence for the preventative activity of NSAIDs in prostate cancer. 
Zhang et al. (2010), showed the suppression of cellular growth by G1 arrest at low 
concentrations (<10 μmol/l); and at higher concentrations (≥10 μmol/l) suppression was 
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associated with caspase-mediated apoptosis. Shebl et al. (2012), analysed patient data from 
29,450 men aged between 55-74 in relation to prostate cancer risk. Daily aspirin use, but not 
ibuprofen, reduced prostate cancer risk. It is though that the inhibition of COX and cell 
proliferation in combination with induced apoptosis is responsible. Similarity in a study by 
Dhillon et al. (2011), showed a 10% lower risk of prostate cancer incidence in patients taking 
two adult-strength aspirin tablets weekly. Again it is though that the combination of 
inhibition of cell proliferation and COX; and induction of apoptosis was responsible. 
Salinas et al. (2010), showed a reduction in prostate cancer risk by 21% in aspirin users 
compared with non-users. This study identified the involvement of PTGS enzymes and 
inhibition of cell proliferation. 
There also seems to be evidence that a relationship exists between NSAIDs and the 
generation of ROS in the micronucleus assay (Kim and Yu, 2014), as found in the present 
study in the micronucleus and the Comet assay. This work seems to support the suggestion 
that NSAIDs on a nano scale could be advantageous for patients and thus influence future 
therapies. 
 The focus of NSAID use has mainly centred on gastrointestinal (GI) side effects and 
potential cardiovascular toxicity. American, Indian and Japanese manufactures are 
developing new and innovative NSAID technologies in early attempts at mitigating GI 
toxicity with oral agents combined with gastroprotective additives. Contemporary 
technologies coupled with uniquely advanced pharmaceutical manipulations to improve 
safety and efficacy are important for future therapies. For examples using combination 
therapies such as: combining the vasodilating agent naproxcinod as the prototypical 
cyclooxygenase-inhibiting nitric oxide (NO) donor, hydrogen sulfide-releasing compounds to 
protect GI mucosa; glycoscience technologies combining the intra-articular hyaluronic-acid-
48 
 
SI-613 (Seikagaku Corporation) with NSAIDs and nano-formulated SoluMatrix™ (iCeutica), 
submicron technologies that include diclofenac, indomethacin, naproxen, and meloxicam 
(Atkinson et al., 2013). 
To completely avoid or to limit the toxicity of a drug and its side effects are one of the major 
benefits which can come from nano-therapeutics. To prevent the therapeutic drug from being 
exposed systemically, and directing the response to a desired organ or cell type, will both 
improve the overall prognosis and treatment time. A good example of this has recently been 
seen in a study carried out on the association between cancer and long-term aspirin therapy. 
A 100mg low dose was administered in healthy (female) volunteers and a statistically 
noticeable improvement was seen in the common side effects such as gastrointestinal 
bleeding and peptic ulcers. However no improvements in cancer or colorectal polyps were 
seen (Cook et al., 2013). 
 There is more evidence (Coghill et al., 2012) that shows a chemopreventive effect for aspirin 
and other NSAIDs on colorectal cancer and other cancer types such as prostate cancer 
(Kawahara et al., 2010), oesophageal (Kang et al., 2013), gastric (Tian et al., 2010) and breast 
cancer (Brasky et al., 2011, Retsky et al., 2012). 
 The present study is the only one to our knowledge where the effects of the particle size of 
these compounds have been investigated at the cellular level in prostate cancer. Our use of 
lymphocytes is supported by the observations of the WHO/IPCS (Albertini et al., 2000)  who 
reported that lymphocytes are suitable surrogate cells for cancer, and our further work 
showing that they are suitable surrogates not only for cancer but also for other disease states 
(Najafzadeh et al., 2012), because DNA is the same in all cells of an individual. 
The micronucleus assay (Fenech, 2000) was used for measuring the cytogenetic damage from 
exposure of our chemicals of interest. The study of DNA damage at the chromosome level is 
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an essential part of genetic toxicology because chromosomal mutation is an important event 
in carcinogenesis. The micronucleus assay has emerged as one of the preferred methods for 
assessing chromosome damage because it enables both chromosome loss and chromosome 
breakage to be measured reliably and is included in the OECD guidelines. Certain chemicals 
can be mutagenic or clastogenic and may lead to the induction of micronuclei in cells at the 
interphase stage. This occurs as a consequence of interference with chromosome structure 
and/or segregation (Kirsch-Volders et al., 2003, Fenech, 2007, Fenech, 2002). 
New research on molecular mechanisms of AD has brought new strategies for therapeutic 
intervention. Neuroprotection using a combination of NSAIDs, antioxidants and oestrogens 
could inhibit the early stages of AD. Nanotechnology may prove to be useful in future AD 
drug delivery strategies, especially drug carrier nano- or microsystems to limit the side- 
effects of anti-Alzheimer drugs (Di Stefano et al., 2011). Similarly, aspirin may protect from 
colorectal cancer (Cook et al., 2013) alongside its original role. 
Earlier in our studies we demonstrated that DES had a response on blood in the Comet assay. 
Although DES is a therapeutic compound, it can have unwanted effects due to doses. There is 
evidence to suggest that an alteration in the prescribed dosing of such therapeutic drugs can 
have a direct positive effect on patients by decreasing or completely preventing side effects 
by using a nanotised form to treat prostate cancer. Work carried out by Koong and Watson, 
(2014) describes the benefits that nano drugs could play on treatments. DES and other 
pharmaceutical oestrogens have been used at >/= microM concentrations to treat advanced 
prostate tumours. 
5.2 Future work 
1. The present work on the genotoxicity of oestrogenic compounds begs the question of 
whether androgens also have the potential for genotoxicity Therefore, a range of 
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compounds such as testosterone, dihydrotestosterone and androstenedione should be 
examined in the Comet and micronucleus assays (in the first instance).   
2. In the literature little or no work has been undertaken on nanotising known 
carcinogens and comparing their effects against bulk versions. Therefore, work should 
be performed on the nanotisation of carcinogens to determine whether this affects 
their genotoxicity.  
3. Does the administration of nanotised selective oestrogen receptor modulators have an 
effect on the risk of developing breast or ovarian cancer? Tamoxifen is an extremely 
useful drug in the treatment of some breast cancer but it has both oestrogenic and anti-
oestrogenic properties and is not effective in all circumstances. It would be highly 
appropriate therefore to test the effect of nanotised tamoxifen on the growth and 
development of breast and breast cancer cells in vitro to assess whether this 
influenced the effect of tamoxifen on those cells.  
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